Otonomy Inc., of San Diego, said the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through status and established a new billing code for Otiprio (ciprofloxacin otic suspension), a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement, which will become effective July 1.